GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 727-734

  Acosta Colman, Isabel ^a   Palau, Núria ^a   Tornero, Jesús ^b   Fernández Nebro, Antonio ^c   Blanco, Francisco ^d   González Alvaro, Isidoro ^e   Cañete, Juan D ^f   Maymó, Joan ^g   Ballina, Javier ^h   Fernández Gutiérrez, Benjamín ⁱ   Olivé, Alex ^j   Corominas, Héctor ^k   Erra, Alba ^l   Canela Xandri, Oriol ^a   Alonso, Arnald ^a   López Lasanta, Maria ^a   Tortosa, Raül ^a   Julià, Antonio ^a   Marsal, Sara ^a  

^a Hospital Vall DHebron   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d UNIVERSITY OF A CORUÑA   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k Moises Broggi Hospital Sant Joan d'Espì   (Spain)

^l Hospital Sant Rafael   (Spain)

more..

Author keywords

anti TNF therapy; biomarker; EULAR response; genetic predictor; rheumatoid arthritis; single nucleotide polymorphism

Indexed keywords

ADALIMUMAB; ETANERCEPT; GENOMIC DNA; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CBLN2 GENE; COHORT ANALYSIS; DENMARK; DRUG RESPONSE; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAP2K6 GENE; NR2FR2 GENE; PDE3A SCLCO1C1 GENE; REPLICATION STUDY; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DENMARK; FEMALE; GENETIC LOCI; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877648835     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.60     Document Type: Article

References (23)

1. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594-1602 (2000).
2. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6, 75-92 (2007).
3. Marsal S, Julia A. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics 11, 617-619 (2010).
4. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14, 575-581 (2008).
5. Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res. Ther. 12, R72 (2010).
6. Krintel SB, Palermo G, Johansen JS, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFa inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22, 577-589 (2012).
7. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63, 645-653 (2011).
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
9. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41, 1845-1850 (1998).
10. So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet. Epidemiol. 35, 310-317 (2011).
11. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol. 52, 135-151 (2012).
12. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38, 778-801 (2008).
13. Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671-680 (2001).
14. Shenoy P, Agarwal V. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun. Rev. 9, 511-515 (2010).
15. Prabhakar U, Lipshutz D, Bartus JO, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF a production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16, 805-816 (1994).
16. Co MS, Queen C. Humanized antibodies for therapy. Nature 351, 501-502 (1991).
17. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36, 159-167 (2006).
18. Morton NE, Collins A. Tests and estimates of allelic association in complex inheritance. Proc. Natl Acad. Sci. USA 95, 11389-11393 (1998).
19. Plenge RM, Bridges SL Jr. Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum. 63, 590-593 (2011).
20. The Comprehensive R Archive Network. http://cran.r-project.org
21. Gene × Environment, Gene × Gene Interaction (Quanto). http://hydra.usc.edu/gxe
22. Genetic Power Calculator. http://pngu.mgh.harvard.edu/~purcell/gpc
23. Metal -Meta Analysis Helper. www.sph.umich.edu/csg/abecasis/metal/index. html